Yes, of course there is a difference in the ligand and isotope, but in terms of indications of cancer being targeted, those two companies acquired products pipeline and clarity's seems quite similar.
in terms of assess the possible value of cu6s pipeline, using that as a comparison seems reasonable, as I would think that the value is based off peak sales of indications.
Ann: Northstar Achieves Key Production Milestones, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.03 |
Change
-0.270(4.29%) |
Mkt cap ! $1.899B | |||
| Open | High | Low | Value | Volume |
| $6.30 | $6.45 | $5.65 | $13.43M | 2.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14784 | $5.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.04 | 4000 | 2 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |